Form 4: Astronics Corp Executive James Mulato Reports Stock Transactions
SEC Form 4 Filing
James Mulato, President of Astronics Test Systems, reports acquisition and disposal of Astronics Corp stock and derivative securities, including options and restricted stock units, in a recent SEC filing.
Summary
- James Mulato, President of Astronics Test Systems, filed a Form 4 with the SEC detailing changes in his beneficial ownership of Astronics Corp [ATRO] securities.
- On March 8, 2024, Mulato acquired 7,838 shares of common stock and 210 shares of common stock for $0.
- On March 8, 2024, Mulato disposed of 1,909 shares of common stock at $18.9 and 51 shares of common stock at $18.9.
- These transactions involved the vesting of restricted stock units, some of which are contingent on Astronics Corp's average annual adjusted EBITDA over specific periods.
- Mulato directly owns 34,211.744 shares of common stock following the reported transactions.
- Mulato also indirectly owns 100 shares of common stock and 32 shares of Class B stock through his spouse.
- Mulato holds various options to purchase common stock and Class B stock at prices ranging from $9.74 to $35.61, with expiration dates extending to 2033.
- He also holds restricted stock units that will vest based on the company's performance.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing primarily reports routine stock transactions related to executive compensation. The vesting of restricted stock units suggests that some performance targets have been met, but the disposal of shares is likely for tax purposes and doesn't necessarily indicate a negative outlook.
Positives
- The vesting of restricted stock units indicates that certain performance targets related to Astronics Corp's adjusted EBITDA have been met, at least partially.
Negatives
- The disposal of 1,909 shares of common stock at $18.9 and 51 shares of common stock at $18.9 could be interpreted negatively, although it is likely related to tax obligations upon vesting of restricted stock units.
Risks
- The vesting of a significant portion of Mulato's restricted stock units depends on Astronics Corp's future adjusted EBITDA performance, which is subject to various economic and business risks.
- Failure to meet the EBITDA targets could result in fewer restricted stock units vesting.
Future Outlook
The vesting of future restricted stock units is contingent on the company's ability to achieve certain adjusted EBITDA targets, indicating a focus on financial performance.
Industry Context
Executive stock transactions are common and are closely watched by investors for insights into management's confidence in the company's future prospects. The vesting of performance-based equity awards aligns management's interests with those of shareholders.
Comparison to Industry Standards
- Performance-based equity compensation is a common practice among publicly traded companies, particularly in the aerospace and defense industries where Astronics operates.
- Companies like HEICO Corporation and TransDigm Group also utilize performance-based metrics, including EBITDA and revenue growth, to determine executive compensation.
- The vesting percentages (50%-150% of target) are within the typical range for such awards.
Stakeholder Impact
- The vesting of performance-based equity awards aligns management's interests with those of shareholders, potentially driving value creation.
- Employees may be motivated by the company's focus on achieving EBITDA targets, which can impact their own compensation and job security.
Next Steps
- Monitor Astronics Corp's financial performance to assess the likelihood of future restricted stock unit vesting.
- Track future insider transactions for further insights into management's sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2015 | Date of exercisable options |
| 12/11/2015 | Date of exercisable options |
| 12/03/2016 | Date of exercisable options |
| 12/14/2017 | Date of exercisable options |
| 12/12/2018 | Date of exercisable options |
| 12/13/2019 | Date of exercisable options |
| 12/09/2020 | Date of exercisable options |
| 01/01/2021 | Start date for EBITDA performance period for restricted stock units |
| 01/22/2022 | Date of exercisable options |
| 01/01/2022 | Start date for EBITDA performance period for restricted stock units |
| 12/09/2022 | Date of exercisable options |
| 01/01/2023 | Start date for EBITDA performance period for restricted stock units |
| 12/16/2023 | Date of exercisable options |
| 12/31/2023 | End date for EBITDA performance period for restricted stock units |
| 01/01/2024 | Start date for EBITDA performance period for restricted stock units |
| 03/08/2024 | Date of reported transactions (acquisition/disposal of shares and vesting of restricted stock units) |
| 03/12/2024 | Date of filing |
| 12/07/2024 | Date of exercisable options |
| 02/24/2025 | Potential vesting date for restricted stock units based on EBITDA performance |
| 01/01/2025 | Start date for EBITDA performance period for restricted stock units |
| 02/23/2026 | Potential vesting date for restricted stock units based on EBITDA performance |
| 01/01/2026 | Start date for EBITDA performance period for restricted stock units |
| 02/22/2027 | Potential vesting date for restricted stock units based on EBITDA performance |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.